OncoMatch/Clinical Trials/NCT06544655
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Is NCT06544655 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for advanced solid tumors.
Treatment: BMS-986484 · Nivolumab · Oxaliplatin · Capecitabine · Fluorouracil · Calcium folinate — The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- START Midwest · Grand Rapids, Michigan
- Sanford Cancer Center · Sioux Falls, South Dakota
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify